Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Persistent Atrial Fibrillation, Cardiac Arrhythmia, Catheter Ablation

In brief

The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.

Key facts

Study ID

NCT06096246

Run by

Barts & The London NHS Trust

People needed

208

Starts

2024-07-26

Expected to finish

2027-12-05

Last updated by the study team

2025-09-03

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to give informed consent
• Age 18-85 years
• Persistent AF (atrial fibrillation lasting > 7days) of total continuous duration <2 years as documented in medical notes.
• Patients being considered for cardioversion.

You may not qualify if…

• Creatinine clearance (eGFR) < 30mls/min
• Contraindication or unable to take anticoagulation
• Uncontrolled hypertension
• Contraindication for catheter ablation
• BMI > 40
• Patients in Persistent AF who have had more than one previous cardioversion.
• Established diagnosis of Hypertrophic cardiomyopathy

Where it is running

• Barts Heart Centre — London, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.